Press review 2014
„Predicting response to neoadjuvant therapy in esophageal cancer with p53 genotyping: A fortune-teller’s crystal ball or a viable prognostic tool?“ – mehr lesen
The Journal of Thoracic and Cardiovascular Surgery, 4. Dezember 2014
„Strategy for prevention of cancers of the esophagus.“ – mehr lesen
Annals of the New York Academy of Sciences (New York), Oktober 2014
„The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes.“ – mehr lesen
The Journal of Thoracic and Cardiovascular Surgery, 3. September 2014
“Das Prädiktor-Gen – ein Paradigmenwechsel” – mehr lesen
Ärzte exklusiv, Aug.–Sept. 2014
Diagnose per Molekül – mehr lesen
ChemieReport.at, Mai 2014
ABOUT 
With the Mark53 analysis, our company is making available a precise p53 gene test, which – for the first time – establishes the prerequisites for a broad clinical application of this biomarker. For the question, as to which patient responds to a cancer therapy and which does not, is a crucial one! We wish to pave the way for an efficient cancer therapy and continue to guarantee research that is independent of the pharmaceutical industry.